Latest Capital Strategy News

Beetaloo Energy has secured full underwriting for its $5 million Share Purchase Plan, with shareholder approval for the share issuance and any shortfall shares to be sought at the upcoming AGM on 29 May 2026.

ColCap Financial Limited (ASX:TT6) reported a 16% rise in net profit to $72.2 million for FY2025, driven by a 15% expansion in its loan portfolio to $19.3 billion and a series of record Residential Mortgage-Backed Securities issuances.

Bank of Queensland has finalised the sale of its equipment finance portfolio to Challenger for $3.62 billion, marking a pivotal step in its strategic transformation. The transaction sets the stage for potential shareholder returns through a buyback and special dividend, pending approvals.

Key Petroleum Ltd has wrapped up the last 3% tranche of its share placement, raising nearly $59,000 and exhausting its 15% ASX placement limit. The fresh capital is earmarked for asset acquisitions, development, and working capital.

Jayride Group continues its pivot to a SaaS mobility platform across Australasia and Southeast Asia, managing tight cash flow and planning a capital raise to sustain operations and support ASX reinstatement.

Scentre Group has successfully tendered 89% of its US$1.312 billion 2030 subordinated notes and plans to redeem the remainder, boosting liquidity to A$3.2 billion while maintaining 4% growth targets for 2026.

Regis Healthcare expects FY26 underlying EBITDA of approximately $135 million, buoyed by near-record occupancy and a disciplined capital strategy amid evolving government reforms.

Microba Life Sciences reported a 99% year-on-year surge in core testing revenue for Q3 FY26, propelled by strong test volume growth and new clinic contracts in Australia and the UK. The company is advancing a major product release and negotiating a significant corporate transaction to bolster its financial position.

Estrella Resources has initiated Timor-Leste’s inaugural hard rock mineral extraction at its Ira Miri manganese project, advancing towards full-scale mining and simultaneously progressing a major limestone resource at Werumata.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Fat Prophets Global Contrarian Fund (ASX: FPC) is raising up to $8.45 million through a pro-rata rights issue priced at a premium, offering one option per new share. The issue is partly underwritten and sees directors committing to full participation.

Metro Mining has secured shareholder approval for a 1-for-20 share consolidation, cutting its shares on issue from over 6.1 billion to roughly 307 million. The move aims to streamline the capital structure and attract broader investor interest.